A novel, simplified cost-value analysis tool was created to better differentiate the value of anticancer agents and further characterize the expected survival benefit of all patients.
Samuel Wagner, PhD
Advertisement
Articles by Samuel Wagner, PhD
Advertisement
Latest Updated Articles
- An Expanded Portfolio of Survival Metrics for Assessing Anticancer Agents
Published: January 17th 2017 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis
2
Dual JAK Inhibition Demonstrates Efficacy in Progressive Nonsegmental Vitiligo
3
ERS Posters Showcase Nerandomilast Benefits in IPF, ILD
4
Nerandomilast a "No-Brainer" for First-Line Pulmonary Fibrosis Therapy: Justin M. Oldham, MD, PhD, MS
5
